A rating of 98 puts Cara Therapeutics Inc (CARA) near the top of the Biotechnology industry according to InvestorsObserver. Cara Therapeutics Inc's score of 98 means it scores higher than 98% of stocks in the industry. Cara Therapeutics Inc also received an overall rating of 73, putting it above 73% of all stocks. Biotechnology is ranked 90 out of the 148 industries.
What do These Ratings Mean?
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 73 means the stock is more attractive than 73 percent of stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Cara Therapeutics Inc Stock Today?
Cara Therapeutics Inc (CARA) stock is down -1.33% while the S&P 500 is higher by 0.96% as of 1:03 PM on Thursday, Apr 15. CARA is lower by -$0.38 from the previous closing price of $28.52 on volume of 657,129 shares. Over the past year the S&P 500 is higher by 49.62% while CARA is higher by 102.01%. CARA earned $0.18 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 159.64.
Click Here to get the full Stock Score Report on Cara Therapeutics Inc (CARA) Stock.
